Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Multi-Center, Randomized Clinical Trial to Evaluate the Efficacy and Safety of Human Anti-SARS-CoV-2 Convalescent Plasma in Severely Ill Adults With COVID-19

NCT04359810 is registered in ClinicalTrials.gov with Max O'Donnell as lead sponsor.

NCT NCT04359810
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04359810 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Multi-Center, Randomized Clinical Trial to Evaluate the Efficacy and Safety of Human Anti-SARS-CoV-2 Convalescent Plasma in Severely Ill Adults With COVID-19
Lead sponsor
Max O'Donnell
Phase
Phase 2
Overall status
Completed
Start date
April 21, 2020
Completion date
December 30, 2020
Enrollment
223 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

sars-cov-2 infection